BIO vs QQQ Stock Comparison

BIO currently leads QQQ in this stock comparison, with AIQ scores of 73 vs 48. The clearest difference is value, while QQQ has the stronger quality profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 25 points
BIO
Healthcare
vs
QQQ
Equity
BIO
Bio-Rad Laboratories, Inc.
Leads
Price
$370
Day move
+3.34%
AIQ Score
73/100
Best edge
Value
Sector
Healthcare
QQQ
Invesco QQQ Trust, Series 1
Price
$660
Day move
+0.39%
AIQ Score
48/100
Best edge
Quality
Sector
Equity

What is the main difference between BIO and QQQ?

BIO leads the current stock comparison as Bio-Rad Laboratories, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Bio-Rad Laboratories, Inc. vs Invesco QQQ Trust, Series 1

Data as of Nov 18, 2026· market close· BIO (stock) vs QQQ (ETF)· Coverage 62/66 fields· 42/42 directly comparable· Moderate confidence
AIQ VerdictStableAIQ Comparison Conviction 10/10

BIO leads

BIO leads by 25 AIQ points, primarily on Value and Risk Resilience, and the lead has widened from 10 points over 30 sessions.

Stable: 4 of 4 evidence groups support BIO, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 4 of 4Comparison trend: Strengthening
BIO

Bio-Rad Laboratories, Inc.

Leads
AIQ Score
73/100
AIQ Edge Score
10/10
QQQ

Invesco QQQ Trust, Series 1

AIQ Score
48/100
AIQ Edge Score
4/10

The Algovestiq AIQ Score currently favors BIO over QQQ, 73 versus 48 as of Nov 18, 2026. BIO's advantage is driven primarily by stronger value and risk resilience, while QQQ holds the stronger quality profile. BIO also shows the stronger technical structure relative to its 50-day moving average. 4 of 4 covered evidence groups favor BIO today, and the comparison is rated Stable on stability: the lead has swung materially session to session. BIO lead: Strengthening — the AIQ differential moved from 10 to 25 points over 30 sessions.

Compare Bio-Rad Laboratories, Inc. and Invesco QQQ Trust, Series 1 across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

BIO
-51.1%
QQQ
+70.2%

Total return comparison

Growth of $10,000, distributions reinvested

BIO $4,886 · QQQ $17,015

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare BIO and QQQ against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BIO advantage
0
QQQ advantage
  • Value80 vs 13
    BIO +67
  • Risk Resilience74 vs 31
    BIO +43
  • Momentum79 vs 38
    BIO +41
  • Quality61 vs 93
    QQQ +32

4 of 4 evidence groups favor BIO. BIO’s edge is concentrated in value and risk resilience; QQQ keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

BIO0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
QQQ+1 AIQ

Largest factor move: Momentum +4

New signals

  • Price Lost 200-Day MA — bearish, trend, long horizon
  • Drawdown Recovery Signal — bullish, risk_regime, long horizon (-14.8%)

BIO's lead narrowed by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — BIO and QQQ both carry a full feed there.

The central trade-off

BIO (Bio-Rad Laboratories, Inc.): the stronger current systematic profile, led by value and risk resilience.

QQQ (Invesco QQQ Trust, Series 1): the counter-case, on quality.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BIO

BIO on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

Even

Growth figures are not covered for both names.

Value

BIO

BIO on the peer-relative Value factor, by 67 points.

Momentum

BIO

BIO on the Momentum factor, by 41 points.

Lower downside

BIO

BIO on Risk Resilience, by 43 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ Agreement Matrix

4 of 4 covered evidence groups favor BIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBIO73 vs 48
FundamentalsNot coveredNot covered
ValuationBIOValue 80 vs 13
TechnicalsBIOPrice vs 50-day -0.7% vs -8.1%; vs 200-day 15.6% vs -0.3%
Risk ResilienceBIORisk Resilience 74 vs 31
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BIO and QQQ and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 25 points. (supports the conclusion holding)
  • 4 of 4 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The lead has swung materially session to session. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BIO.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

BIO lead: Strengthening — the AIQ differential moved from 10 to 25 points over 30 sessions.

Jun 1BIO leads above the line · QQQ leads belowNov 18
Today
BIO +25
73 vs 48
7 sessions ago
BIO +27
75 vs 48
30 sessions ago
BIO +10
72 vs 62
90 sessions ago
BIO +17
73 vs 56

The lead changed hands once in this window, most recently on Jun 2 when BIO moved ahead of QQQ.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only BIO

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.56%)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • TRIX Bullish Signal — bullish, momentum, short horizon
QQQConflicted

2 bullish / 1 bearish, conflicted

Only QQQ

  • Price Lost 200-Day MA — bearish, trend, long horizon
  • Drawdown Recovery Signal — bullish, risk_regime, long horizon (-14.8%)

Both carry 1 more signal that do not separate them: Golden Cross Active.

BIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BIONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.34%, AIQ 0 points).

QQQConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.39%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1QQQ closes the Value gap — currently 67 points behind, the largest single contributor to BIO's edge.
  2. 2QQQ's Price Lost 200-Day MA resolves — a bearish trend rule currently active against it.
  3. 3BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

Split
MetricBIOQQQ
Revenue growth (YoY)0.8%—
EPS growth (YoY)23.3%—
Gross margin51.3%—
Operating margin4.6%—
Return on equity (TTM)6%—
Debt to equity0.18—

Performance

BIO leads 5 of 6 windows
MetricBIOQQQ
1 week (5 sessions)-4%3.6%
1 month (20 sessions)3.6%-4.2%
3 months (63 sessions)3.1%-6.8%
6 months (126 sessions)48%-4.1%
Year to date20.9%10.7%
1 year (252 sessions)11.9%9.5%

Technicals

BIO has the stronger structure
MetricBIOQQQ
RSI (14)45.442.8
ADX (14)12.930.3
Price vs 50-day-0.7%-8.1%
Price vs 200-day15.6%-0.3%
Volatility (1M, annualized)31.4%35.4%

Risk

BIO is the more resilient
MetricBIOQQQ
Beta0.731.46
Sharpe ratio0.470.44
Sortino ratio0.690.62
Max drawdown-27.2%-14.8%
Current drawdown-6.1%-10.5%
Annualized volatility36.2%21.5%
Value at risk (95%)-3%-2%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BIO or QQQ?

On the Algovestiq AIQ Score, BIO is the stronger of the two as of Nov 18, 2026, scoring 73 against QQQ's 48. The edge comes from value and risk resilience. QQQ is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BIO or QQQ the better buy right now?

BIO carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Stable — 4 of 4 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor BIO over QQQ?

The composite weights Quality, Value, Momentum and Risk Resilience. BIO leads Value by 67 points; BIO leads Risk Resilience by 43 points; BIO leads Momentum by 41 points. Where the two split, the factor with the larger weight carries the result.

Which is better value, BIO or QQQ?

BIO is the better-valued of the two on the peer-relative Value factor. BIO on the peer-relative Value factor, by 67 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BIO or QQQ?

Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BIO or QQQ?

BIO on the Momentum factor, by 41 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BIO or QQQ?

BIO is the more resilient of the two, so the other name carries the higher downside risk. BIO on Risk Resilience, by 43 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BIO more profitable than QQQ?

Margin data is not comparable for both names in the current snapshot.

Is BIO's lead over QQQ getting stronger or weaker?

BIO lead: Strengthening — the AIQ differential moved from 10 to 25 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has changed hands once in that window, most recently on 2026-06-02, when BIO moved ahead of QQQ.

What would change the BIO vs QQQ verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: QQQ closes the Value gap — currently 67 points behind, the largest single contributor to BIO's edge; QQQ's Price Lost 200-Day MA resolves — a bearish trend rule currently active against it; BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about BIO and QQQ?

BIO: 3 bullish / 2 bearish / 1 neutral, conflicted. QQQ: 2 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BIO is Golden Cross Active (bullish, long horizon). On QQQ it is Golden Cross Active (bullish, long horizon).

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.